9/14/2023 0 Comments Prognostic factor![]() ![]() First, the association of TET2 mutations with other genetic alterations has not been fully addressed. There are several unresolved issues relating to TET2 mutations in primary AML. ![]() 2-14 The studies concerning clinical implications of TET2 mutation in patients with primary AML are scarce. 1 Subsequent studies using the same methods, direct sequencing, or next-generation sequencing confirmed that mutations in this gene were prevalent in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasms, myeloproliferative neoplasms, and secondary acute myeloid leukemia (AML), with frequencies ∼ 10%-26%, 22%-58%, 7%-13%, and 24%-32%, respectively. Mutations in Ten-Elevan-Translocation-2 ( TET2) were first discovered in myeloid malignancies by high-resolution single nucleotide polymorphism (SNP) and comparative genomic hybridization arrays. TET2 mutation appeared to be unstable during disease evolution. In conclusion, TET2 mutation is associated with poor prognosis in AML patients with intermediate-risk cytogenetics, especially when it is combined with other adverse molecular markers. Sequential analysis revealed that TET2 mutation detected at diagnosis was frequently lost at relapse rarely, the mutation was acquired at relapse in those without TET2 mutation at diagnosis. A scoring system integrating TET2 mutation with FLT3-ITD, NPM1, and CEBPA mutations could well separate AML patients with intermediate-risk cytogenetics into 4 groups with different prognoses ( P <. TET2 mutation is an unfavorable prognostic factor in patients with intermediate-risk cytogenetics, and its negative impact was further enhanced when the mutation was combined with FLT3-ITD, NPM1-wild, or unfavorable genotypes (other than NPM1 +/ FLT3-ITD − or CEBPA +). TET2 mutation occurred in 13.2% of our patients and was closely associated with older age, higher white blood cell and blast counts, lower platelet numbers, normal karyotype, intermediate-risk cytogenetics, isolated trisomy 8, NPM1 mutation, and ASXL1 mutation but mutually exclusive with IDH mutation. We analyzed TET2 mutation in 486 adult patients with primary AML. I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.The studies concerning clinical implications of TET2 mutation in patients with primary acute myeloid leukemia (AML) are scarce. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). ![]() I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as. Funding StatementĪll relevant ethical guidelines have been followed any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.Īll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. The authors have declared no competing interest. Meanwhile, old age (≥ 60 yrs, RR = 9.45 95% CI, 8.09-11.04), followed by cardiovascular disease (RR = 6.75 95% CI, 5.40-8.43) hypertension (RR = 4.48 95% CI, 3.69-5.45) and diabetes (RR = 4.43 95% CI, 3.49-5.61) were found to be independent prognostic factors for the COVID-19 related death.Ĭonclusions To our knowledge, this is the first evidence-based medicine research to explore the risk factors of prognosis in patients with COVID-19, which is helpful to identify early-stage patients with poor prognosis and adapt effective treatment. In terms of laboratory results, increased lactate dehydrogenase (LDH), C-reactive protein (CRP) and D-dimer and decreased blood platelet and lymphocytes count were highly associated with severe COVID-19 (all for P < 0.001). Results A total of 30 studies including 53000 patients with COVID-19 were included in this study, the mean age was 49.8 years (95% CI, 47.5-52.2 yrs) and 55.5% were male. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |